Compliance with new drug use and the effect of discrepant drug susceptibility testing on MDR/RR-TB treatment
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q2
- 저널
- INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE28(2) · pp.18 · 2024
- 피인용
- Web of Science 1Scopus 1
- FWCI (Scopus)
- 0.18
- JCR IF
- JCR 2023 3.8
- ISSN
- 1027-3719
저자
- Shin, J. E.제1저자Asan Med Ctr, Div Pulm & Crit Care Med, Seoul, South Korea
- 전두수Pusan Natl Univ, Yangsan Hosp, Dept Internal Med, Yangsan, South Korea
- 목정하Pusan Natl Univ Hosp, Dept Internal Med, Busan, South Korea
- Yim, J. -j.Seoul Natl Univ, Coll Med, Dept Internal Med, Div Pulm & Crit Care Med, Seoul, South Korea
- Kwon, Y-s.Chonnam Natl Univ Hosp, Dept Internal Med, Gwangju, South Korea
- Jo, K. -w.Univ Ulsan, Coll Med, Div Pulm & Crit Care Med, Seoul, South Korea
- Shim, T. S.교신저자Asan Med Ctr, Div Pulm & Crit Care Med, Seoul, South Korea
초록
BACKGROUND: Following the WHO???s announcement in 2018, the use of new drugs was recommended for all patients with multidrug-resistant TB (MDR-TB) in Korea. This study aimed to evaluate adherence to new anti-TB drug regimens and implementation of molecular drug susceptibility testing (mDST) in Korea.METHODS: Nationwide, 560 patients were reported as having MDR-TB in 2021. The implementation of mDST and new anti-TB drug use were analysed. The discrepancy between mDST and phenotypic DST (pDST) results and their implications on the use of new anti-TB drugs were also analysed. The use of novel anti-TB drugs has been approved by the National TB Expert Committee.RESULTS: The non-adherence rate in MDR-TB patients was 14.3%. The mDST implementation rate was 96.1%. Of the 459 patients who underwent both mDST and pDST, the discordance rate for rifampicin (RIF) resistance was 22.6% (n = 104), of which 72.1% (n = 75) were resistant on mDST but susceptible on pDST. The discrepancy in mDST and pDST results related to RIF resistance was found to be the main cause of non-adherence to new drug regimen.CONCLUSION: Comprehensive training on how to interpret conflicting results between mDST and pDST could enhance the utilisation of new drugs in the treatment of MDR/RIF-resistant TB.
키워드
MULTIDRUG-RESISTANT TUBERCULOSISMYCOBACTERIUM-TUBERCULOSISTREATMENT OUTCOMESRIFAMPINBEDAQUILINEDELAMANID
식별자
- Scopus EID
- 2-s2.0-85184344650
- WoS UID
- 001222190700002



로그인
연구물 목록으로